XyloCor Therapeutics is focused on improving the lives of people with cardiovascular disease through our commitment to advancing the science of gene therapy.
Press Release: July 27, 2021
XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina
XyloCor’s proprietary products address significant unmet clinical needs in cardiovascular disease.
XyloCor’s products are enabled by proprietary gene therapy technologies from Weill Cornell Medical College.